Atreca Inc

NASDAQ:BCELUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Contact Information

Headquarters

835 Industrial Road , 75 SHOREWAY ROAD, SUITE CSAN CARLOS, CA, United States 94070

Phone

650-595-2595

Fax

650-453-2410

Executives

Independent Chairman of the Board

Brian Atwood

President, Chief Executive Officer, Principal Financial Officer, Director

John Orwin

Chief Strategy Officer, Co-Founder, Director

Tito Serafini

Principal Accounting Officer

Rick Ruiz

Chief Scientific Officer

Stephen Gould